WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on ...

Though its eponym in Greek mythology was able to successfully defeat the fire-breathing chimera, Bellerophon Therapeutics’ story is closing out on a much less victorious note. The New Jersey ...

Bellerophon Therapeutics Inc (NASDAQ: BLPH) entered into a license agreement for the development and commercialization of INOpulse with Baylor BioSciences. Under the terms of the license agreement ...

Bellerophon has granted the underwriters of the Underwritten Offering a 30-day option to purchase up to an additional 288,461 shares of common stock at the public offering price, ...

Bellerophon Therapeutics Stock Performance BLPH opened at $0.01 on Monday. The firm has a market cap of $146,796.00, a P/E ratio of -0.01 and a beta […] Skip to main content ...

WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing ...